Kenox Pharmaceuticals

Executive Summary

Kenox Pharmaceuticals is a US-based contract development and manufacturing organization (CDMO) specializing in aerosol-based drug delivery for orally inhaled and nasal drug products (OINDP) and ophthalmic formulations. Founded in 2016 and headquartered in Princeton, New Jersey, the company offers end-to-end services from formulation design and analytical development to clinical manufacturing. By focusing on complex delivery systems, Kenox enables pharmaceutical and biotech partners to accelerate the development of inhaled and intranasal therapies, which are increasingly sought for respiratory diseases, central nervous system disorders, and systemic drug delivery via the lung or nasal mucosa. The CDMO model provides recurring revenue and reduces binary risk compared to drug developers, as Kenox's growth is tied to the success of multiple client programs rather than a single product. With the global inhaled drug delivery market expected to exceed $50 billion by 2030, Kenox is well-positioned to capture demand from both large pharma and emerging biotechs seeking specialized aerosol expertise.

Upcoming Catalysts (preview)

• Q3 2026New strategic partnership with a top-20 pharma for OINDP development70% success
• Q4 2026Expansion of manufacturing capacity or new aerosol platform launch60% success
• Q1 2027First client program achieves positive Phase 2 results or advances to Phase 350% success